Drug establishmentActive, Registered FY2026FDA warning letter on file

Bodywell Natural Skin Care Inc

Bodywell Natural Skin Care Inc is an FDA-registered drug establishment (FEI 3018011294) located in . The facility is active, registered for FY2026. FDA has issued 1 warning letter(s) to this facility.

FDA warning letter

Mar 27, 2024
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

A warning letter is FDA's formal notice of significant violations that require prompt correction. It can hold up product approvals, trigger import alerts, and put supply agreements at risk until the issues are resolved and FDA closes it out.

Recalls (1)

Jun 21, 2019 Class II
CGMP Deviations: products were manufactured with lack of process validation, cleaning validation, stability studies, and other current good manufacturing practice violations.

Recall data from openFDA enforcement reports (FDA Recall Enterprise System).

Establishment record

FEI Number
3018011294
Address
Unit 3- 7338 Progress Way, ,
Establishment type
Drug establishment
Products / operations
Manufacturing
Registration status
Active, Registered FY2026

Verify this record on FDA.gov ›

Inspection history

Inspections on file
None on file
Form 483 observations
None on file

FDA publishes only a subset of inspection records and Form 483s, so "None on file" is not a guarantee of a clean inspection history.

Questions

Is Bodywell Natural Skin Care Inc registered with the FDA?

Yes. Bodywell Natural Skin Care Inc is an FDA-registered drug establishment (FEI 3018011294) in . Its current registration status is Active, Registered FY2026.

Has Bodywell Natural Skin Care Inc received an FDA warning letter?

Yes. FDA issued a warning letter to Bodywell Natural Skin Care Inc; the most recent is dated Mar 27, 2024 (CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug).

What does Bodywell Natural Skin Care Inc do?

Bodywell Natural Skin Care Inc's FDA-registered operations are: Manufacturing.

Related facilities

Source: FDA public data · status as of 2026-06-06

The Quality Brief

Every new FDA drug and device warning letter and recall, summarized once a week. Free.